Brief: Amneal Launches Mesalamine And Receives U.S. FDA Approval For Lenalidomide
19/02/2025 15:06
Feb 19 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O :
* AMNEAL LAUNCHES MESALAMINE AND RECEIVES U.S. FDA APPROVAL
FOR
LENALIDOMIDE
Source text: ID:nBw2tmz5Fa
Further company coverage: AMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study